TIL
Instil Bio·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 0
Consensus Rating "Strong Buy"
Ample Liquidity
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About TIL
Instil Bio, Inc.
A clinical-stage biopharmaceutical company that focused on developing tumor infiltrating lymphocyte therapies for cancer
3963 Maple Avenue, Suite 350, Dallas, Texas 75219
--
Instil Bio, Inc., headquartered in Dallas, Texas, was incorporated in Delaware in August 2018. The Company is a clinical-stage biopharmaceutical company developing innovative autologous tumor infiltrating lymphocyte (TIL) therapeutic cell therapies to treat cancer patients.
Company Financials
EPS
TIL has released its 2025 Q3 earnings. EPS was reported at -2.01, versus the expected -3.04, beating expectations. The chart below visualizes how TIL has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
